Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes
Status: | Recruiting |
---|---|
Conditions: | Peripheral Vascular Disease |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 11/24/2018 |
Start Date: | January 2013 |
End Date: | January 2033 |
Contact: | Ishita Tejani, BDS,MS,MSPH |
Email: | ishita.tejani@utsouthwestern.edu |
Phone: | 2148573048 |
Multi-Center Registry Comparing Stent and Non-Stent Based Interventional Outcomes for Patients With Peripheral Arterial Disease
XLPAD is an observational study designed to evaluate the effectiveness and use of stent and
non-stent based therapies among PAD patients. The study will create a registry that will
include entry of procedural and clinical follow-up information into an online data collection
software, REDCAP.Data available since Jan 1 2005 will be included in the registry, until
14,000 patients have been included. The primary objectives of this observational registry
study are to:
1. Compare stent and non-stent based outcomes defined as a composite of symptom driven
target vessel revascularization (TVR), unplanned surgical revascularization of the
target limb and need for target limb amputation through 12 months post-index procedure
(Primary efficacy endpoint)
2. Compare stent and non-stent based outcomes defined as a composite of causes such as:
death, myocardial infarction (MI), stroke, peri-procedural complications, target vessel
revascularization (TVR) and unplanned surgical revascularization/amputation of the
target limb through 12 months (Primary safety endpoint)
3. Compare stent and non-stent based change in walking distance, Rutherford category and/or
ankle- brachial index (ABI) at 12 months compared to baseline (Primary clinical
improvement endpoint)
Approximately 14,000patients will be enrolled at approximately 60 sites worldwide. Enrollment
in the observational study will be monitored in an effort to achieve at least 20% (and no
more than 80%) of the population receiving stents as the initial treatment strategy.
Follow-up visits by sites will be reported at 6 and 12 months after index procedure to
collect data on treatment patterns and effectiveness, and outcomes. The follow-up procedures
are not mandated by the registry protocol. Each site will be encouraged to enter follow-up
information derived from clinically indicated follow-up visits. All events post-index
procedure till the 7th month will be reported under the 6 month follow-up form and subsequent
follow-up till the 13th month post-procedure will be entered on the 12 month follow-up form.
Patient management and treatment decisions are at the discretion of the care team per routine
clinical practice. The procedural aspects (including selection of stent type or non-stent
based treatments) and follow-up are not mandated by the registry and will be up to the
discretion of the operator and/or based upon the practice dictated by the clinical care of
the patient. Therefore the study poses minimal risk to the patient.
non-stent based therapies among PAD patients. The study will create a registry that will
include entry of procedural and clinical follow-up information into an online data collection
software, REDCAP.Data available since Jan 1 2005 will be included in the registry, until
14,000 patients have been included. The primary objectives of this observational registry
study are to:
1. Compare stent and non-stent based outcomes defined as a composite of symptom driven
target vessel revascularization (TVR), unplanned surgical revascularization of the
target limb and need for target limb amputation through 12 months post-index procedure
(Primary efficacy endpoint)
2. Compare stent and non-stent based outcomes defined as a composite of causes such as:
death, myocardial infarction (MI), stroke, peri-procedural complications, target vessel
revascularization (TVR) and unplanned surgical revascularization/amputation of the
target limb through 12 months (Primary safety endpoint)
3. Compare stent and non-stent based change in walking distance, Rutherford category and/or
ankle- brachial index (ABI) at 12 months compared to baseline (Primary clinical
improvement endpoint)
Approximately 14,000patients will be enrolled at approximately 60 sites worldwide. Enrollment
in the observational study will be monitored in an effort to achieve at least 20% (and no
more than 80%) of the population receiving stents as the initial treatment strategy.
Follow-up visits by sites will be reported at 6 and 12 months after index procedure to
collect data on treatment patterns and effectiveness, and outcomes. The follow-up procedures
are not mandated by the registry protocol. Each site will be encouraged to enter follow-up
information derived from clinically indicated follow-up visits. All events post-index
procedure till the 7th month will be reported under the 6 month follow-up form and subsequent
follow-up till the 13th month post-procedure will be entered on the 12 month follow-up form.
Patient management and treatment decisions are at the discretion of the care team per routine
clinical practice. The procedural aspects (including selection of stent type or non-stent
based treatments) and follow-up are not mandated by the registry and will be up to the
discretion of the operator and/or based upon the practice dictated by the clinical care of
the patient. Therefore the study poses minimal risk to the patient.
Patients undergoing an endovascular intervention receiving either stents or percutaneous
transluminal angioplasty (PTA) to the superficial femoral, popliteal, peroneal, anterior
tibial, or posterior tibial arteries will be entered into this registry. Patients undergoing
treatment of the external or common iliac arteries are not admissible to the registry, unless
these arteries were treated in addition to one of the five aforementioned arteries. The
registry will collect data in the form of patient background information, procedural data,
and follow-up data from the patient's medical records. Data available since Jan 1 2005 will
be included in the registry, until 14,000 patients have been included. The data will be
entered into a software, REDCAP, that automatically provides data quality verification and
processing.
Specifically, the data fields collected by the registry will be:
I) Background Information
1. Site, attending operator, and month-year of procedure
2. Patient height, weight, age, race, and sex
3. Rutherford claudication category, left and right ankle brachial index, ambulatory
status, claudication free distance
4. Risk factors such as diabetes, hypertension, hyperlipidemia, and prior history of lower
extremity percutaneous intervention
5. Patient comorbidities such as coronary artery disease, congestive heart failure, prior
myocardial infarction, stroke, transient ischemic attack, chronic kidney disease, and
other.
II) Lesion Characteristics (enter data for up to five lesions)
1. Access site relative to target limb, sheath size, target limb (left or right)
2. Target vessel: superficial femoral artery, popliteal artery, peroneal artery, anterior
tibial artery, or posterior tibial artery
3. Which, if any, Iliac arteries were treated during procedure
4. Target lesion location (ostial, proximal, medial, distal), estimated vessel diameter,
estimated vessel length
5. Lesion characteristics (heavily calcified, diffuse, thrombus, chronic total occlusion
(CTO), in-stent restenosis, restenosis post balloon angioplasty, profunda femoris
disease)
6. Planned revascularization strategy: stent or non-stent based
IIa) CTO Characteristics (Only required for CTO lesions)
1. Type of proximal and distal stumps, sidebranches present, collateral filling of distal
vessel, tortuosity, prior attempt to cross CTO
2. Antegrade or retrograde crossing strategy, crossing technique, number of attempts
3. Crossing devices used, microcatheters used, sub-intimal re-entry devices used (if any),
embolic protection device used
III) Intervention Details
1. Atherectomy device used (Cutting Balloon, TurboHawk, SilverHawk, Rotablator, Laser)
2. Pre and post-dilation balloon information (type, length, width, average atmospheric
pressure, number of inflations)
3. Stent information (indication for stents, length, width, maximum pressure, overlapping
with previous stents)
4. Aspiration/Thrombectomy used, thrombolytic therapy used
5. Percent change in stenosis and TIMI flows (before and after)
IV) Outcomes
1. Technical success (<30% residual stenosis), procedural success (<30% residual stenosis
without complications), and case comments
2. Anti-coagulation used, medical therapy (plavix, aspirin, lipid lowering therapy,
angiotensin receptor blocker, beta blocker, cilostazol, trental, insulin, oral
hypoglycemics)
3. Duration of procedure, fluoroscopy (amount used, type, and time)
4. Any procedural complications
V) Follow-Up
1. Month and year of follow-up
2. Rutherford category, left and right ankle brachial index, claudication-free distance,
ambulatory status, change in claudication (improved, same, or worsened)
3. Duplex ultrasound performed
4. Adverse events experienced (death, myocardial infarction, stroke, stent thrombosis,
stent fracture, angiography, repeat endovascular intervention, surgical
revascularization, amputation in target or non-target limb)
Follow-up data is recorded from clinical visits six and twelve months after the procedure. If
the patient undergoes a repeat intervention on the target limb, a new record is created for
the procedure.
transluminal angioplasty (PTA) to the superficial femoral, popliteal, peroneal, anterior
tibial, or posterior tibial arteries will be entered into this registry. Patients undergoing
treatment of the external or common iliac arteries are not admissible to the registry, unless
these arteries were treated in addition to one of the five aforementioned arteries. The
registry will collect data in the form of patient background information, procedural data,
and follow-up data from the patient's medical records. Data available since Jan 1 2005 will
be included in the registry, until 14,000 patients have been included. The data will be
entered into a software, REDCAP, that automatically provides data quality verification and
processing.
Specifically, the data fields collected by the registry will be:
I) Background Information
1. Site, attending operator, and month-year of procedure
2. Patient height, weight, age, race, and sex
3. Rutherford claudication category, left and right ankle brachial index, ambulatory
status, claudication free distance
4. Risk factors such as diabetes, hypertension, hyperlipidemia, and prior history of lower
extremity percutaneous intervention
5. Patient comorbidities such as coronary artery disease, congestive heart failure, prior
myocardial infarction, stroke, transient ischemic attack, chronic kidney disease, and
other.
II) Lesion Characteristics (enter data for up to five lesions)
1. Access site relative to target limb, sheath size, target limb (left or right)
2. Target vessel: superficial femoral artery, popliteal artery, peroneal artery, anterior
tibial artery, or posterior tibial artery
3. Which, if any, Iliac arteries were treated during procedure
4. Target lesion location (ostial, proximal, medial, distal), estimated vessel diameter,
estimated vessel length
5. Lesion characteristics (heavily calcified, diffuse, thrombus, chronic total occlusion
(CTO), in-stent restenosis, restenosis post balloon angioplasty, profunda femoris
disease)
6. Planned revascularization strategy: stent or non-stent based
IIa) CTO Characteristics (Only required for CTO lesions)
1. Type of proximal and distal stumps, sidebranches present, collateral filling of distal
vessel, tortuosity, prior attempt to cross CTO
2. Antegrade or retrograde crossing strategy, crossing technique, number of attempts
3. Crossing devices used, microcatheters used, sub-intimal re-entry devices used (if any),
embolic protection device used
III) Intervention Details
1. Atherectomy device used (Cutting Balloon, TurboHawk, SilverHawk, Rotablator, Laser)
2. Pre and post-dilation balloon information (type, length, width, average atmospheric
pressure, number of inflations)
3. Stent information (indication for stents, length, width, maximum pressure, overlapping
with previous stents)
4. Aspiration/Thrombectomy used, thrombolytic therapy used
5. Percent change in stenosis and TIMI flows (before and after)
IV) Outcomes
1. Technical success (<30% residual stenosis), procedural success (<30% residual stenosis
without complications), and case comments
2. Anti-coagulation used, medical therapy (plavix, aspirin, lipid lowering therapy,
angiotensin receptor blocker, beta blocker, cilostazol, trental, insulin, oral
hypoglycemics)
3. Duration of procedure, fluoroscopy (amount used, type, and time)
4. Any procedural complications
V) Follow-Up
1. Month and year of follow-up
2. Rutherford category, left and right ankle brachial index, claudication-free distance,
ambulatory status, change in claudication (improved, same, or worsened)
3. Duplex ultrasound performed
4. Adverse events experienced (death, myocardial infarction, stroke, stent thrombosis,
stent fracture, angiography, repeat endovascular intervention, surgical
revascularization, amputation in target or non-target limb)
Follow-up data is recorded from clinical visits six and twelve months after the procedure. If
the patient undergoes a repeat intervention on the target limb, a new record is created for
the procedure.
Inclusion Criteria:
- Underwent Endovascular Intervention
- Treated Superficial Femoral, Popliteal, Peroneal, Anterior Tibial, or Posterior Tibial
Arteries
Exclusion Criteria:
- Failed Revascularization Attempt
- Surgical Bypass
- Only Iliac Artery Treated
We found this trial at
23
sites
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Khusrow Niazi, MD
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Christopher Bajzer, MD
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Korman Research Pavilion%2c Suite 100
Philadelphia, Pennsylvania 19141
Philadelphia, Pennsylvania 19141
215-456-7215
Principal Investigator: Jon George, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Chicago, Illinois 60141
Principal Investigator: Robert S Dieter, MD
Click here to add this to my saved trials
Corpus Christi, Texas 78404
Principal Investigator: Srikanth Damaraju, MD
Click here to add this to my saved trials
Dallas, Texas 75216
Principal Investigator: Subhash Banerjee, MD
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: Subhash Banerjee, MD
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Click here to add this to my saved trials
3505 Gaston Avenue
Dallas, Texas 75246
Dallas, Texas 75246
Principal Investigator: John F Eidt, MD
Click here to add this to my saved trials
Davenport, Iowa 52803
Principal Investigator: Nicolas Shammas, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Kingsport, Tennessee 37660
Principal Investigator: Christopher Metzger, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Muncie, Indiana 47303
Principal Investigator: M. Ishti Ali, MD
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Principal Investigator: Mazen Abu-Fadel, MD
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73109
Principal Investigator: George Chrysanthakopoulos, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials